A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry

Mahmud Kajbaf; Raffaele Longhi; Dino Montanari; Federica Vinco; Monica Rigo; Stefano Fontano; Kevin D. Read

doi:10.2174/187231211794455262

A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry

Mahmud Kajbaf (Lead / Corresponding author), Raffaele Longhi (Research group member), Dino Montanari (Research group member), Federica Vinco (Research group member), Monica Rigo (Research group member), Stefano Fontano (Research group member), Kevin D. Read

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

Semi-automated high throughput screening for the inhibition of major human cytochrome P450 enzymes (1A2, 2C9, 2C19, 2D6 and 3A4) expressed in Escherichia Coli (Cypex bactosomes) or human lymphoblastoid cells (Gentest
cDNA microsomes) using fluorescent probes has been evaluated using 68 marketed drugs. In general lower IC50 values were obtained with Cypex bactosomes compared with Gentest cDNA microsomes. This could be due to use of higher concentration of protein and also the lower activity of Gentest cDNA microsomes. Notably, when compared with in vivo clinical drug-drug interactions (cDDIs) gathered from clinical studies reported in the scientific literature Cypex bactosome data was better at predicting in vivo cDDI. Consequently, from the data obtained in this comparative study, a fluorescence based assay using Cypex bactosomes is more suitable as a front-line screen for the prediction of potential downstream CYP450 driven cDDIs.

Original language	English
Pages (from-to)	30-39
Number of pages	10
Journal	Drug Metabolism Letters
Volume	5
Issue number	1
DOIs	https://doi.org/10.2174/187231211794455262
Publication status	Published - 2012

Access to Document

10.2174/187231211794455262

Cite this

@article{b9a4e0de08114466a58b6f8ef70c2d48,

title = "A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry",

abstract = "Semi-automated high throughput screening for the inhibition of major human cytochrome P450 enzymes (1A2, 2C9, 2C19, 2D6 and 3A4) expressed in Escherichia Coli (Cypex bactosomes) or human lymphoblastoid cells (GentestcDNA microsomes) using fluorescent probes has been evaluated using 68 marketed drugs. In general lower IC50 values were obtained with Cypex bactosomes compared with Gentest cDNA microsomes. This could be due to use of higher concentration of protein and also the lower activity of Gentest cDNA microsomes. Notably, when compared with in vivo clinical drug-drug interactions (cDDIs) gathered from clinical studies reported in the scientific literature Cypex bactosome data was better at predicting in vivo cDDI. Consequently, from the data obtained in this comparative study, a fluorescence based assay using Cypex bactosomes is more suitable as a front-line screen for the prediction of potential downstream CYP450 driven cDDIs.",

author = "Mahmud Kajbaf and Raffaele Longhi and Dino Montanari and Federica Vinco and Monica Rigo and Stefano Fontano and Read, {Kevin D.}",

year = "2012",

doi = "10.2174/187231211794455262",

language = "English",

volume = "5",

pages = "30--39",

journal = "Drug Metabolism Letters",

issn = "1872-3128",

publisher = "Bentham Science Publishers",

number = "1",

}

A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry. / Kajbaf, Mahmud (Lead / Corresponding author); Longhi, Raffaele (Research group member); Montanari, Dino (Research group member) et al.
In: Drug Metabolism Letters, Vol. 5, No. 1, 2012, p. 30-39.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry

AU - Kajbaf, Mahmud

AU - Read, Kevin D.

A2 - Longhi, Raffaele

A2 - Montanari, Dino

A2 - Vinco, Federica

A2 - Rigo, Monica

A2 - Fontano, Stefano

PY - 2012

Y1 - 2012

N2 - Semi-automated high throughput screening for the inhibition of major human cytochrome P450 enzymes (1A2, 2C9, 2C19, 2D6 and 3A4) expressed in Escherichia Coli (Cypex bactosomes) or human lymphoblastoid cells (GentestcDNA microsomes) using fluorescent probes has been evaluated using 68 marketed drugs. In general lower IC50 values were obtained with Cypex bactosomes compared with Gentest cDNA microsomes. This could be due to use of higher concentration of protein and also the lower activity of Gentest cDNA microsomes. Notably, when compared with in vivo clinical drug-drug interactions (cDDIs) gathered from clinical studies reported in the scientific literature Cypex bactosome data was better at predicting in vivo cDDI. Consequently, from the data obtained in this comparative study, a fluorescence based assay using Cypex bactosomes is more suitable as a front-line screen for the prediction of potential downstream CYP450 driven cDDIs.

AB - Semi-automated high throughput screening for the inhibition of major human cytochrome P450 enzymes (1A2, 2C9, 2C19, 2D6 and 3A4) expressed in Escherichia Coli (Cypex bactosomes) or human lymphoblastoid cells (GentestcDNA microsomes) using fluorescent probes has been evaluated using 68 marketed drugs. In general lower IC50 values were obtained with Cypex bactosomes compared with Gentest cDNA microsomes. This could be due to use of higher concentration of protein and also the lower activity of Gentest cDNA microsomes. Notably, when compared with in vivo clinical drug-drug interactions (cDDIs) gathered from clinical studies reported in the scientific literature Cypex bactosome data was better at predicting in vivo cDDI. Consequently, from the data obtained in this comparative study, a fluorescence based assay using Cypex bactosomes is more suitable as a front-line screen for the prediction of potential downstream CYP450 driven cDDIs.

U2 - 10.2174/187231211794455262

DO - 10.2174/187231211794455262

M3 - Article

SN - 1872-3128

VL - 5

SP - 30

EP - 39

JO - Drug Metabolism Letters

JF - Drug Metabolism Letters

IS - 1

ER -

A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry

Abstract

Access to Document

Fingerprint

Cite this